// App-Quantinova.ai

Su1933 : FILGOTINIB (GLPG0634, GS-6034), A JAK-1 SELECTIVE INHIBITOR, SIGNIFICANTLY REDUCES GUT TISSUE PSTAT3 IN Crohn's DISEASE PATIENTS

Researchers

Presenter

  • Brian G. Feagan

Principal Investigators

  • Gert De Hertogh

  • Yang Pan

  • Severine Vermeire

  • Guang Chen

  • Dorothy M. French

  • Erik G. Huntzicker

  • Annegret Van der Aa

  • Tim Van Kaem

  • Pille Harrison

  • Chantal T. Tasset

  • Rene Galien

Medical Centers

  • Robarts Reserach Institute, London, ON, Canada

  • University of California San Diego, CA, United States

  • Galapagos SASU, Romainville, Belgium

Locations

  • United States

  • Canada

  • Belgium

Companies

  • Gilead Sciences, Inc

  • Galapagos NV

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • Phosphorylated signal transducer and activator of transcription 3

Drug/Treatment

  • Filgotinib

  • L-Tyrosine

Outcome

  • Unknown

Study Design

  • randomized

  • pharmacodynamics

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved